Dual inhibition of monoamine oxidase B and antagonism of the adenosine A 2A receptor by (E, E)-8-(4-phenylbutadien-1-yl) caffeine analogues

J Pretorius, SF Malan, N Castagnoli, JJ Bergh…

Index: Pretorius, Judey; Malan, Sarel F.; Castagnoli Jr., Neal; Bergh, Jacobus J.; Petzer, Jacobus P. Bioorganic and Medicinal Chemistry, 2008 , vol. 16, # 18 p. 8676 - 8684

Full Text: HTML

Citation Number: 56

Abstract

The adenosine A2A receptor has emerged as an attractive target for the treatment of Parkinson's disease (PD). Evidence suggests that antagonists of the A2A receptor (A2A antagonists) may be neuroprotective and may help to alleviate the symptoms of PD. We have reported recently that several members of the (E)-8-styrylcaffeine class of A2A antagonists also are potent inhibitors of monoamine oxidase B (MAO-B). Since MAO-B ...